New immune therapy trial targets Tough-to-Treat skin cancer

NCT ID NCT06981325

Recruiting now Disease control Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Source: ClinicalTrials.gov ↗

Summary

This study is testing whether the immunotherapy drug cemiplimab can help control advanced basal cell carcinoma when used as the first treatment. The trial will enroll about 34 adults with locally advanced skin cancer that cannot be treated with surgery or radiation. Participants will receive cemiplimab infusions every three weeks for up to one year while researchers monitor how well the cancer responds and track side effects.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BASAL CELL CARCINOMA (BCC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Helios Klinikum Erfurt
RECRUITING

Erfurt, Germany
Helios Klinikum Oberhausen
RECRUITING

Oberhausen, Germany
Johannes Wesling Klinikum
RECRUITING

Minden, Germany
Nationales Centrum für Tumorerkrankungen (NCT)
RECRUITING

Heidelberg, Germany
Universitätsklinikum Erlangen
RECRUITING

Erlangen, Germany
Universitätsklinikum Leipzig
RECRUITING

Leipzig, Germany
Universitätsklinikum Tübingen
RECRUITING

Tübingen, Germany

Conditions

Explore the condition pages connected to this study.

BASAL CELL CARCINOMA (BCC) FIRST LINE TREATMENT